Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial

Krishnamurthi, 2014, The global burden of hemorrhagic stroke: a summary of findings from the GBD 2010 study, Glob Heart, 9, 101, 10.1016/j.gheart.2014.01.003 Mayer, 2008, Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage, N Engl J Med, 358, 2127, 10.1056/NEJMoa0707534 Hanley, 2019, Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial, Lancet, 10.1016/S0140-6736(19)30195-3 Huang, 2002, Brain edema after experimental intracerebral haemorrhage: role of hemoglobin degradation products, J Neurosurg, 96, 287, 10.3171/jns.2002.96.2.0287 Wagner, 2003, Heme and iron metabolism: role in cerebral haemorrhage, J Cereb Blood Flow Metab, 23, 629, 10.1097/01.WCB.0000073905.87928.6D Nakamura, 2004, Deferoxamine-induced attenuation of brain edema and neurological deficits in a rat model of intracerebral haemorrhage, J Neurosurg, 100, 672, 10.3171/jns.2004.100.4.0672 Gu, 2009, Deferoxamine reduces intracerebral haematoma induced iron accumulation and neuronal death in piglets, Stroke, 40, 2241, 10.1161/STROKEAHA.108.539536 Okauchi, 2010, Deferoxamine treatment for intracerebral haemorrhage in aged rats: therapeutic time window and optimal duration, Stroke, 41, 375, 10.1161/STROKEAHA.109.569830 Selim, 2011, Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral haemorrhage, Stroke, 42, 3067, 10.1161/STROKEAHA.111.617589 Kothari, 1996, The ABCs of measuring intracerebral haemorrhage volumes, Stroke, 27, 1304, 10.1161/01.STR.27.8.1304 Hemphill, 2001, The ICH score: a simple, reliable grading scale for intracerebral haemorrhage, Stroke, 32, 891, 10.1161/01.STR.32.4.891 Cases, 1988, Acute visual and auditory neurotoxicity in patients with end-stage renal disease receiving desferrioxamine, Clin Nephrol, 29, 176 Savio, 2013, Reliability of the modified Rankin Scale applied by telephone, Neurol Int, 5, e2, 10.4081/ni.2013.e2 Hanley, 2016, Safety and efficacy of minimally invasive surgery plus alteplase in intracerebral haemorrhage evacuation (MISTIE): a randomised, controlled, open-label, phase 2 trial, Lancet Neurol, 15, 1228, 10.1016/S1474-4422(16)30234-4 Mayer, 2005, Recombinant activated factor VII for acute intracerebral hemorrhage, N Engl J Med, 352, 777, 10.1056/NEJMoa042991 Lyden, 2007, Safety and tolerability of NXY-059 for acute intracerebral hemorrhage: the CHANT trial, Stroke, 38, 2262, 10.1161/STROKEAHA.106.472746 Haley, 2005, Gavestinel does not improve outcome after acute intracerebral hemorrhage: an analysis from the GAIN International and GAIN Americas studies, Stroke, 36, 1006, 10.1161/01.STR.0000163053.77982.8d Qureshi, 2016, Intensive blood-pressure lowering in patients with acute cerebral hemorrhage, N Engl J Med, 375, 1033, 10.1056/NEJMoa1603460 Yeatts, 2013, High dose deferoxamine in intracerebral haemorrhage (Hi-Def) trial: rationale, design, and methods, Neurocrit Care, 19, 257, 10.1007/s12028-013-9861-y Hanley, 2017, Thrombolytic removal of intraventricular haemorrhage in treatment of severe stroke: results of the randomised, multicentre, multiregion, placebo-controlled CLEAR III trial, Lancet, 389, 603, 10.1016/S0140-6736(16)32410-2 Mehdiratta, 2008, Association between serum ferritin level and perihematoma edema volume in patients with spontaneous intracerebral hemorrhage, Stroke, 39, 1165, 10.1161/STROKEAHA.107.501213 Tenenbein, 1992, Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning, Lancet, 339, 699, 10.1016/0140-6736(92)90598-W 2018, Unmet needs and challenges in clinical research of intracerebral haemorrhage, Stroke, 49, 1299, 10.1161/STROKEAHA.117.019541 Lees, 2016, Early versus late assessment of stroke outcome, Stroke, 47, 1416, 10.1161/STROKEAHA.115.011153 Wilson, 2013, Time course of recovery following poor-grade SAH: the incidence of delayed improvement and implications for SAH outcome study design, J Neurosurg, 119, 606, 10.3171/2013.4.JNS121287 Lee, 2015, The motor recovery related with brain lesions in patients with intracranial haemorrhage, Behav Neurol, 2015, 258161, 10.1155/2015/258161 Sreekrishnan, 2017, Functional improvement among intracerebral haemorrhage survivors up to 12 months post-injury, Neurocrit Care, 27, 326, 10.1007/s12028-017-0425-4 Yu, 2017, Effects of deferoxamine mesylate on haematoma and perihaematoma edema after traumatic intracerebral haemorrhage, J Neurotrauma, 34, 2753, 10.1089/neu.2017.5033 Yu, 2015, The clinical effect of deferoxamine mesylate on edema after intracerebral haemorrhage, PLoS One, 10, e0122371, 10.1371/journal.pone.0122371 Staykov, 2011, Natural course of perihemorrhagic edema after intracerebral haemorrhage, Stroke, 42, 2625, 10.1161/STROKEAHA.111.618611 Palesch, 2005, Applying a phase II futility study design to therapeutic stroke trials, Stroke, 36, 2410, 10.1161/01.STR.0000185718.26377.07 He, 2008, Autophagy after experimental intracerebral haemorrhage, J Cereb Blood Flow Metab, 28, 897, 10.1038/sj.jcbfm.9600578